{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:24:25Z","timestamp":1787739865733,"version":"build-2784847793"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T00:00:00Z","timestamp":1670630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T00:00:00Z","timestamp":1670630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s10549-022-06765-3","type":"journal-article","created":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T14:02:31Z","timestamp":1670680951000},"page":"603-612","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Relationship between tamoxifen and cataracts: a nationwide cohort study of women in South Korea"],"prefix":"10.1007","volume":"197","author":[{"given":"Chang Ik","family":"Yoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Sun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soyoung","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dooreh","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1265-1981","authenticated-orcid":false,"given":"Woo-Chan","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,10]]},"reference":[{"key":"6765_CR1","first-page":"315","volume":"62","author":"MI Kaiser-Kupfer","year":"1978","unstructured":"Kaiser-Kupfer MI (1978) Tamoxifen retinopathy. Cancer Treat Rep 62:315\u2013320","journal-title":"Cancer Treat Rep"},{"key":"6765_CR2","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1136\/bmj.304.6825.495","volume":"304","author":"CR Bentley","year":"1992","unstructured":"Bentley CR, Davies G, Aclimandos WAJBBMJ (1992) Tamoxifen retinopathy: a rare but serious complication. BMJ 304:495","journal-title":"BMJ"},{"key":"6765_CR3","first-page":"420","volume":"21","author":"EW Gerner","year":"1989","unstructured":"Gerner EW (1989) Ocular toxicity of tamoxifen. Ann Ophthalmol 21:420\u2013423","journal-title":"Ann Ophthalmol"},{"key":"6765_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1755-3768.1983.tb01393.x","volume":"61","author":"T Vinding","year":"1983","unstructured":"Vinding T (1983) Retinopathy caused by treatment with tamoxifen in low dosage. Acta Ophthalmol 61:45\u201350","journal-title":"Acta Ophthalmol"},{"key":"6765_CR5","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1172\/JCI117514","volume":"94","author":"JJ Zhang","year":"1994","unstructured":"Zhang JJ, Jacob T, Valverde MA, Hardy SP, Mintenig GM, Sepulveda FV, Gill D, Hyde S (1994) Tamoxifen blocks chloride channels. A possible mechanism for cataract formation. J Clin Investig 94:1690\u20131697","journal-title":"J Clin Investig"},{"key":"6765_CR6","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1200\/jco.2010.34.0141","volume":"30","author":"DC Allred","year":"2012","unstructured":"Allred DC, Anderson SJ, Paik S, Wickerham DL, Nagtegaal ID, Swain SM, Mamounas EP, Julian TB, Geyer CE Jr, Costantino JP, Land SR, Wolmark N (2012) Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol 30:1268\u20131273. https:\/\/doi.org\/10.1200\/jco.2010.34.0141","journal-title":"J Clin Oncol"},{"key":"6765_CR7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/s1470-2045(10)70266-7","volume":"12","author":"J Cuzick","year":"2011","unstructured":"Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, Forbes JF, Bishop H, Fentiman IS, George WD (2011) Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK\/ANZ DCIS trial. Lancet Oncol 12:21\u201329. https:\/\/doi.org\/10.1016\/s1470-2045(10)70266-7","journal-title":"Lancet Oncol"},{"key":"6765_CR8","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/jnci\/93.9.684","volume":"93","author":"B Fisher","year":"2001","unstructured":"Fisher B, Dignam J, Bryant J, Wolmark N (2001) Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the national surgical adjuvant breast and bowel project B-14 randomized trial. J Natl Cancer Inst 93:684\u2013690. https:\/\/doi.org\/10.1093\/jnci\/93.9.684","journal-title":"J Natl Cancer Inst"},{"key":"6765_CR9","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"EBCTCGJT Lancet","year":"2005","unstructured":"Lancet EBCTCGJT (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687\u20131717","journal-title":"Lancet"},{"key":"6765_CR10","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","volume":"90","author":"B Fisher","year":"1998","unstructured":"Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N (1998) Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 90:1371\u20131388","journal-title":"J Natl Cancer Inst"},{"key":"6765_CR11","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1093\/aje\/kwq224","volume":"172","author":"PC Austin","year":"2010","unstructured":"Austin PC (2010) Statistical criteria for selecting the optimal number of untreated subjects matched to each treated subject when using many-to-one matching on the propensity score. Am J Epidemiol 172:1092\u20131097. https:\/\/doi.org\/10.1093\/aje\/kwq224","journal-title":"Am J Epidemiol"},{"key":"6765_CR12","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1093\/jnci\/djk049","volume":"99","author":"J Cuzick","year":"2007","unstructured":"Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K (2007) Long-term results of tamoxifen prophylaxis for breast cancer\u201496-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99:272\u2013282","journal-title":"J Natl Cancer Inst"},{"key":"6765_CR13","unstructured":"Prevention CfDCa International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM). In:"},{"key":"6765_CR14","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0002-9394(99)80190-1","volume":"125","author":"MB Gorin","year":"1998","unstructured":"Gorin MB, Day R, Costantino JP, Fisher B, Redmond CK, Wickerham L, Gomolin JE, Margolese RG, Mathen MK (1998) Long-term tamoxifen citrate use and potential ocular toxicity. Am J ophthalmol 125:493\u2013501","journal-title":"Am J ophthalmol"},{"key":"6765_CR15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1023\/B:BREA.0000041626.76694.85","volume":"87","author":"BD Bradbury","year":"2004","unstructured":"Bradbury BD, Lash TL, Kaye JA (2004) Tamoxifen and cataracts: a null association. Breast Cancer Res Treat 87:189\u2013196","journal-title":"Breast Cancer Res Treat"},{"key":"6765_CR16","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1016\/0277-5379(89)90351-9","volume":"25","author":"S Longstaff","year":"1989","unstructured":"Longstaff S, Sigurdsson H, O\u2019Keeffe M, Ogston S (1989) A controlled study of the ocular effects of tamoxifen in conventional dosage in the treatment of breast carcinoma. Eur J Cancer Clin Oncol 25:1805\u20131808","journal-title":"Eur J Cancer Clin Oncol"},{"key":"6765_CR17","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1023\/A:1006342300291","volume":"60","author":"A Paganini-Hill","year":"2000","unstructured":"Paganini-Hill A (2000) Eye problems in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 60:167\u2013172","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"6765_CR18","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.clbc.2022.02.002","volume":"22","author":"F Canino","year":"2022","unstructured":"Canino F, Omarini C, Cerma K, Moscetti L, Tornincasa A, Trudu L, Dominici M, Piacentini FJCBC (2022) Ocular toxicity in breast cancer management: manual for the oncologist. Clin Breast Cancer 22(4):289\u2013299","journal-title":"Clin Breast Cancer"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06765-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-022-06765-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06765-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T05:32:20Z","timestamp":1674797540000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-022-06765-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,10]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["6765"],"URL":"https:\/\/doi.org\/10.1007\/s10549-022-06765-3","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,10]]},"assertion":[{"value":"4 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The protocol was approved by the Institutional Review Board (Local IRB Number: KC22ZISI0340) of Seoul St Mary\u2019s Hospital. The need for informed consent was waived by the IRB due to the retrospective study design.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"All authors have given consent for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}